Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SCIEX : OS Introduces New Software With OneOmics Suite and Molecule Profiler App

06/17/2021 | 11:02am EDT

New introductions connect breakthrough technology to biological insight in a secure, cloud-based environment

SCIEX, a global leader in life science analytical technologies, continues to strengthen its software portfolio with new applications. OneOmics suite, now commercialized, supports big data, multi-omics research through the power of secure, collaborative cloud computing on SCIEX Cloud. The Molecule Profiler app extends beyond traditional drug metabolism software to add capabilities for the identification and quantification of biopharmaceutical metabolites and impurities, and provides a single solution to support the safety of life-saving therapies.

SCIEX OS is an entire LC-MS software ecosystem that enables scientists to easily get the most out of every sample. It is continually being updated to meet the evolving workflow needs of our customers, including support for the ZenoTOF 7600 system, the new accurate mass system from SCIEX. Systems powered by SCIEX OS have intuitive data acquisition, powerful data processing, and data integrity through traceable audit trails. Soon to be available in 9 languages, SCIEX OS helps scientists ensure completeness and consistency across all labs, instruments and workflows.

SCIEX Cloud and OneOmics suite

To advance the detection and treatment of disease, it is critical to understand how the thousands of mRNA transcripts, proteins, lipids and metabolites in the body are regulated and modified. The large-scale study of these molecules is the field of omics. OneOmics suite enables life science researchers to process large-scale proteomics and metabolomics data sets with ease, and up to 10x faster than desktop computing, reducing processing time from hours to minutes.

With SCIEX Cloud, data are securely stored in the cloud, allowing researchers to process their data from anywhere, anytime, and collaborate globally to integrate data from transcriptomics, proteomics and metabolomics. These increases in productivity will support breakthrough discoveries in the field of biomarker research.

To learn more about OneOmics suite and SCIEX Cloud, see here.

Molecule Profiler app

To bring life-saving small molecule and biopharmaceutical therapies to market safely, it is critical to understand how they are metabolized in the body. Molecule Profiler enables scientists to identify and quantify biotransformations and impurities across a wide range of molecular classes, including therapeutic oligonucleotides, small molecule drugs, peptide therapeutics and antibody-drug conjugates.

Combined with the superior sensitivity of the ZenoTOF 7600 system, it becomes easy to detect low-level metabolites and understand their in vivo metabolism, ensuring that these revolutionary therapies can be brought to market faster.

“Software is the vital connector between technology and insights, that will drive discovery. Our customers told us that the new horizon in disease research is multi-omics, and we listened. They told us that the new frontier of next-generation biologics is oligonucleotide-based therapies, and we listened. We are proud to introduce software that prioritizes user experience and diversity of need, thus enabling the vision of our customers.”
-
Beth Hazell, Senior Director of Software at SCIEX.

To learn more about Molecule Profiler app, see here.

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher (NYSE: DHR) family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com.

Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-13461-A.


ę Business Wire 2021
All news about DANAHER CORPORATION
06:01aDANAHER : Beckman Coulter's new urinalysis solution improves laboratory workflow by signif..
PR
09/21DANAHER : Schedules Third Quarter 2021 Earnings Conference Call
PR
09/15DANAHER CORP /DE/ : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
09/14DANAHER : Keeps Quarterly Cash Dividend Unchanged at $0.21 a Share, Payable Oct. 29 to Sha..
MT
09/14DANAHER : Announces Quarterly Dividends
PR
09/14Danaher Corporation Approves Regular Quarterly Cash Dividend, Payable on October 29, 20..
CI
09/10DANAHER : Credit Suisse Raises Danaher's PT to $370 from $306, Notes Heightened Conviction..
MT
09/08DANAHER : RBC Raises Price Target on Danaher to $332 From $304 Ahead of Analyst Day, Maint..
MT
09/03DANAHER : Helping Customers Make Better Beer -- and Improve Sustainability
PU
09/01SCIEX : Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 Syste..
BU
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Financials (USD)
Sales 2021 28 681 M - -
Net income 2021 6 136 M - -
Net Debt 2021 15 202 M - -
P/E ratio 2021 38,1x
Yield 2021 0,28%
Capitalization 226 B 226 B -
EV / Sales 2021 8,40x
EV / Sales 2022 7,78x
Nbr of Employees 68 000
Free-Float 74,2%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 316,00 $
Average target price 322,47 $
Spread / Average Target 2,05%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos GutiÚrrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors